samedi 17 octobre 2009

Squalène, Guerre du Golfe, contamination bactérienne, corruption et industrie de l'armement: bienvenue chez les vaccins PowderJect/ Chiron/ Novartis


#Edition revue et augmentée#
La compagnie PowderJect Pharmaceuticals a été fondée en 1993 par Lord Drayson en Grande Bretagne. La compagnie obtient de gros contrat du gouvernement pour des traitements antivarioliques après que Lord Drayson a fait d'importantes donations au parti travailliste britannique.En octobre 2000 Lord Drayson achète une usine de vaccins à Speke près de Liverpool, c'est cette usine qui fabrique aujourd'hui les vaccins contre le virus de la grippe H1N1 pour le compte de la compagnie Novartis.
Une enquête de la BBC (voir infra) déclare que "pendant qu'il était propriétaire de l'usine, il y a eu nombre de problèmes avec quatre différents vaccins: polio, grippe, hépatite A, et plus inquiétant le vaccin TB (BCG) fourni au National Health Service britannique.Lord Drayson a refusé l'invitation de l'émission Money Program. Des documents officiels de la MHRA, l'autorité britannique de régulation de la santé, et obtenus par l'emission Money Program, montrent que la compagnie a elle même réalisé les contrôles de ses propres vaccins TB (BCG). [...]Alors que les problèmes avec les vaccins TB sont un echec alarmant de l'usine PowderJect, trois différentes autorités de régulation de la santé (Britannique, Américaine et Irlandaises) se sont plaintes de manière répétée à l'encontre des injections de vaccins du BCG, de la polio, et de l'hépatite fabriqués par l'usine PowderJect. La MHRA britannique a visité 16 fois l'usine pendant que PowderJect était proptiétaire. La FDA américaine l'a visité deux fois en 2001 et une fois en 2003. Ils ont découvert une "situation significativement très mauvaise" dans l'usine, et mis a jour que quatre des cinq lots de vaccin destinés au marché américain ont échoué aux tests de rayon-vie; et peut être le plus inquiétant de tout: une contamination bactérienne du procédé industriel de fabrication pour les injections de grippe. Des bactéries incluant la Klebsialla Oxytoca et la Serratia ont été identifiées dans la zone de l'usine où le vaccin contre la grippe était fabriqué. En 2003 Mr Drayson a vendu PowderJect à Chiron, un géant pharmaceutique américain, pour plus de 500 millions de livres sterlings. Un an plus tard la ligne de production de vaccins contre la grippe était fermée par la FDA. Le résultat a été une grave pénurie de vaccins contre la grippe sur le marché américain."
En 2005 Lord Drayson devient ministre du gouvernement britannique pour les fournitures militaires, en 2008 ministre pour l'innovation et la recherche, et en 2009 ministre pour la reforme des acquisitions stratégiques militaires.
En 2003 la compagnie de Lord Drayson est rachetée avec une grosse plus value par la compagnie californienne Chiron alors qu'elle a reçu de l'argent public pour son développement. La compagnie Chiron est liée au scandale du syndrome de la guerre du Golfe et à l'adjuvant Squalène. C'est en effet Chiron qui fabrique le vaccin contre le bacille du charbon (anthrax) qui est injecté aux soldats américains lors de la première guerre contre l'Irak (1991). Gary Matsumoto accuse dans un livre ce vaccin contre le bacille du charbon d'être à l'origine des multiples maux dont souffrent les soldats américains qui reviennent de la guerre. "The Covert Government Experiment That's Killing Our Soldiers —and Why GI's Are Only the First Victims": "L'expérimentation clandestine du gouvernement qui tue nos soldats, et pourquoi les GI ne sont seulement que les premières victimes" Gary Matsumoto accuse le département américain de la défense d'avoir secretement rajouté du Squalène dans les vaccins, ce qui aurait causé une série de troubles pathologiques graves sur les corps des soldats.
En 2006 Chiron est racheté par Novartis. Aujourd'hui c'est cette partie de la firme Novartis qui fabrique le vaccin contre le H1N1 à Speke, près de Liverpool.
Photographie: Lord Drayson en train de s'occupper de notre santé...




The irresistible rise of 'Tony's crony'
By Elliot Choueka, BBC Money Programme, http://news.bbc.co.uk/2/hi/business/4446978.stm

Is Lord Drayson the best man for the job?

Paul Drayson is the Labour Party's leading businessman in government.

He was made a lord and then the UK defence procurement minister after giving New Labour more than £1m.

In 2004 he was the party's largest individual donor.

The Money Programme can reveal that he also ran a company which sold faulty TB vaccines and kept quiet about it for 21 months, risking the health of thousands of people.

Needle-free injection system

Paul Rudd Drayson was born and brought up in South London, educated at Catford's private St. Dunstan's school.

He got a degree and a PhD at Aston University, and worked in the car business, before moving on to lead a management buy-out of a division of Trebor, the sweet manufacturer.

He then got into the bio-tech business.

It was a time of growth and boom in the sector and new futuristic inventions were being snapped up by entrepreneurs with an eye for a business opportunity.

It was at Oxford University that Paul spotted the value of a revolutionary needle-free injection system.

With the device's inventor he formed a company to develop the technology.

Powderject was its name.

Making a mint

Dr. John Savopoulos, an analyst at Datamonitor who specialises in the vaccine business, recalls the excitement surrounding the PowderJect device.


There are question marks over how that business was conducted that go to the very heart of Drayson's credibility so he must answer those questions
Henry Bellingham
Conservative MP

"It signed a $300m (£175m) agreement with Glaxo Wellcome at the time, for DNA vaccines." he says.

"It seemed to be present at all the international conferences as a company pushing forward the frontiers."

Although the company attracted millions of pounds worth of investment and floated on the stock market, the Powderject device has never made it to market. It is still being developed.

In October 2000, Powderject bought a vaccine factory in Speke, Liverpool.

It was a move which was to make Mr Drayson's fortune.

Not protected

During his ownership of the factory there were a number of problems with four different vaccines - polio, flu, hepatitis A and most worryingly the TB (BCG) vaccine, supplied to the National Health service in Britain.

Lord Drayson
Lord Drayson declined invites to speak with the Money Programme

Official documents from the MHRA, the UK Health regulator, obtained by the Money Programme show that the company had been carrying out monitoring of its own TB (BCG) vaccines.

The tests showed that from 1989 to 2002, nine batches of the BCG vaccine failed to "meet the end of shelf-life potency criteria", as it is written in the document.

This means the vaccine was no longer as effective as it should have been.

To make matters worse, the MHRA was kept in the dark.

The risk to the public is that of the millions of people - nearly all schoolchildren - who have been vaccinated, an unknown number face the real possibility that their TB vaccines were sub-strength and may not provide immunity.

One unofficial estimate, based on health department figures, is that since the tests began in 1989 - long before Drayson bought the factory - nine batches, that is perhaps as many as 900,000 BCG doses, failed shelf-life tests.

If you take a 2% failure rate - which is what happened when a Powderject sub-batch failed in Ireland - then 18,000 people have been vaccinated but may not be protected from TB.

No-one, and that includes the British government, knows for sure.

Objectionable conditions

Dr Savopoulos says of the non-disclosure: "to produce a vaccine that's given to thousands of school children to protect them against TB and-and the vaccine isn't working, is unforgivable".

Although the problems with the TB vaccine are the most alarming failures at the Powderject plant, three different health regulators - the British, the Americans and the Irish - made repeated complaints about Powderject's TB (BCG), polio, hepatitis and flu jabs.

Britain's MHRA visited the plant 16 times during Powderject's ownership.

Inspectors from the US Food and Drug Administration (FDA) visited the plant twice in 2001 and once in 2003.

They found 'significant objectionable conditions' at the factory, discovered that four out of five flu vaccine batches destined for the US market failed shelf-life tests and, perhaps most worrying of all, bacterial contamination of the manufacturing process for the flu jab.

Bacteria including Klebsialla Oxytoca and Serratia were identified in factory areas where the flu vaccine was manufactured.

In 2003 Mr Drayson sold Powderject to Chiron, an American pharmaceutical giant, for more than £500m.

Just over a year later its flu vaccine production-line was shut down by the FDA.

The result was a mass-shortage of flu vaccine in the American market.

Public inquiry

No-one can doubt Lord Drayson's business acumen.

Along the way he has become a seriously rich man, with him and his family worth an estimated £80m.

He gave more than £1m to the NHS hospital in Oxford where his third son was born, and also more than £1m to New Labour.

He has a million pound motor yacht in Antibes and a £7m chateau in the South of France.

Now Labour MP, Dr Ian Gibson and Conservative MP Henry Bellingham are calling for a public inquiry into the events that brought Lord Drayson such wealth, to ensure public confidence in mass vaccinations and to ensure that nothing untoward occurred at Powderject.

"There are question marks over how that business was conducted that go to the very heart of Drayson's credibility so he must answer those questions," says Mr Bellingham.

"And the government, I think, should make sure that he answers those questions as soon as possible if he is to continue in his office."

Adds Dr Gibson, who is a former chairman of the House of Commons science and technology committee: "I think we need a public inquiry into this whole business."

"Because I think if we're going to produce good flu vaccines and other vaccines, we need to make sure that the process that's making them is above board and there's no corners being cut.

"A public inquiry into this situation would be quite interesting and we'll see where responsibility did lie."

The Money Programme has contacted Lord Drayson for a response to the many issues raised in the programme but has received no reply.

Lord Moneyjabs: How Drayson fattened up his drug firm on the taxpayer - then made £80m selling it to Americans

By Steve Doughty

Last updated at 1:18 AM on 16th June 2009, http://www.dailymail.co.uk/news/article-1193282/Lord-Moneyjabs-How-Drayson-fattened-drug-firm-taxpayer--80m-selling-Americans.html

A Labour donor made a vast personal fortune on the back of a £20million handout of taxpayers' money, an inquiry has found.

Lord Drayson had threatened to pull his PowderJect company out of Britain unless it was given public cash.

In 2003 the vaccine manufacturer was offered the £20million to build a factory by a government-run regional development board.
Rich: Lord Drayson made a vast personal fortune at taxpayers' expense

Rich: Lord Drayson made a vast personal fortune at taxpayers' expense

Just two months later he sold the subsidised company to its U.S. rival Chiron, landing a profit for himself and his family estimated at £80million.

He is now a science minister and, following last week's reshuffle, also a defence minister attending Cabinet meetings. The affair raises disturbing questions over Labour's burgeoning quango network and the way it handles large sums of public money in deep secrecy.

At a time of widespread anger over MPs' misuse of their expenses, it led to calls yesterday for better scrutiny of the way taxpayers' money is spent by unaccountable bureaucrats.

The North West Regional Development Agency, which channelled money to the Drayson firm, is one of nine RDAs which between them have spent more than £15billion.

An official report on the PowderJect deal, which the North West RDA commissioned but unsurprisingly decided not to publish, finds that the takeover which made Lord Drayson's fortune was 'significantly influenced' by the handout from the quango.

It adds that the grant produced a less-than- expected return for the public.

The controversial peer's dealings with Downing Street, Whitehall and the Labour Party have been under scrutiny since when, as Dr Paul Drayson, he made donations totalling £100,000 to Labour funds during 2001 and 2002.

Shortly afterwards PowderJect was handed a £32.5million Government contract to supply smallpox vaccine.

Made a peer by Tony Blair in 2004, Lord Drayson joined the Government the following year and became Gordon Brown's science minister last October.
Ermine-clad crony: Drayson joined the Lords in 2004

Ermine-clad crony: Drayson joined the Lords in 2004

The inquiry into the 'Powder-Ject Project' said the firm asked the Department of Trade and Industry and the RDA for support for 'future investment plans'.

The company said the Dublin government had offered it help to move to Ireland and Powder-Ject's factory at Speke, Liverpool, would eventually be closed if the Eire option were selected, losing 650 jobs.

The DTI was keen to back the firm, says the report by the Amion consultancy. Lord Drayson's company needed a decision quickly 'in order to be ready for the 2007 flu season'.

It adds: 'The process was undertaken over a relatively short time. The initial economic appraisal work commenced in March 2003 and the approval letter was received from the DTI on 20 May 2003.'

The deal, worth £19.85million, was to pay for a new factory, a research lab and staff training. Just under £ 5million was to go directly to PowderJect, the rest to developers building the factory and to training companies.

However, by this stage a complication had arisen. Lord Drayson's company had been the target of a rejected takeover bid by Chiron in autumn 2002.

In April 2003, Chiron was reported to have returned with a much higher offer for the company of more than £540million.

The inquiry says: 'In July 2003 PowderJect was acquired by Chiron. This proposed acquisition was known about at the time of the original product approval and assurances were provided by PowderJect in relation to the proposed project.'
Former Prime Minister: Tony Blair made Lord Drayson a peer in 2004

Former Prime Minister: Tony Blair made Lord Drayson a peer in 2004

Lord Drayson, who was chief executive of PowderJect, is estimated to have personally made more than £40million from the takeover, with his family's profits totalling £80million.

The eventual £14million of public money which went into the project has provided a new vaccine factory in Speke, now operated by a company which later took over Chiron.

However no research lab was built. The report says it is unlikely that the facility will ever materialise and that future state development contracts should ensure companies are held to their commitments.

Conservative communities spokesman Caroline Spelman said: 'It is a symptom of Labour's quango culture that unelected bodies can casually spend £14million of taxpayers' money only to find it barely has any impact on the communities it's supposed to benefit.

'We need proper accountability into the way taxpayers' money is being spent and that means abolishing regional government and establishing from ministers exactly why this money was seemingly put to such poor use.'

Matthew Elliott, of the Tax-Payers' Alliance, said: 'It is scandalous that Lord Drayson was made wealthy by a convenient investment of taxpayers' money.

'The regional development agencies are bad enough when they are trying and failing to do their jobs, but if they have been dishing out grants to political favourites then they are worse than incompetent.'

A spokesman for the Department of Business, Innovation and Skills - the successor to the DTI - said: 'The decision to fund this project was based on comprehensive economic advice by independent consultants.

'It has resulted in the creation of a world-class pharmaceutical manufacturing facility, safeguarded and created nearly 900 jobs in the company and surrounding businesses worth £60million to the local economy and helped 500 people gain valuable new skills.'

Lord Drayson declined to comment.

Read more: http://www.dailymail.co.uk/news/article-1193282/Lord-Moneyjabs-How-Drayson-fattened-drug-firm-taxpayer--80m-selling-Americans.html#ixzz0UBjcyUPW


Anthrax ScareDid the military secretly doctor its anthrax vaccine?
By Jon CohenPosted Tuesday, Nov. 16, 2004, at 4:00 PM ET
http://www.slate.com/id/2109808/


Un projet mondial en vue de préparer les citoyens aux dangeureuses vaccinations
Squalène: un adjuvant toxique dans les futurs vaccins contre la grippe porcine


par Stephen Lendman, Mondialisation.ca, Le 22 aout 2009
http://www.mondialisation.ca/index.php?context=va&aid=14880

Extraits du livre:
http://www.vaccine-a.com/excerpt.html





Novartis veut s'offrir Chiron pour entrer sur le marché des vaccins

Les Echos n° 19490 du 02 Septembre 2005 • page 18
http://archives.lesechos.fr/archives/2005/LesEchos/19490-96-ECH.htm
Novartis poursuit ses emplettes. A peine bouclé l'achat d'Hexal dans les médicaments génériques, le laboratoire suisse veut entrer cette fois-ci sur le marché des vaccins. Il a annoncé hier le lancement d'une OPA sur l'américain Chiron, dont il détient déjà 42 % du capital. La firme bâloise offre ainsi 4,5 milliards de dollars (3,6 milliards d'euros) pour les 58 % qu'elle ne détient pas.

Société de biotechnologies fondée en 1981, Chiron s'est spécialisée dans les vaccins (environ un quart des revenus), les diagnostics sanguins et des médicaments contre les maladies infectieuses et les cancers. Son chiffre d'affaires était de 1,7 milliard de dollars en 2004. La société californienne est le numéro cinq mondial des vaccins, un marché sur lequel elle doit se battre contre des géants de la pharmacie que sont le français Sanofi-Aventis, le britannique GlaxoSmithKline et les américains Wyeth et Merck (voir graphique).

Avec moins de 10 milliards de dollars de chiffre d'affaires annuel, le marché mondial des vaccins reste une niche par rapport aux 400 milliards de l'industrie pharmaceutique. Mais sa croissance est beaucoup plus forte : Lehman Brothers prévoit une progression moyenne de 13 % par an d'ici à 2008, contre 4,4 % pour les médicaments. Des innovations vont arriver, comme les vaccins contre le cancer du col de l'utérus développés par Glaxo et Merck. Et la peur d'une pandémie de grippe aviaire a récemment rappelé leur importance aux pouvoirs publics des pays riches.

Problèmes de production
Novartis sera peut-être obligé de relever son offre : l'action Chiron s'est envolée de 18 % hier à l'ouverture de Wall Street, à 43 dollars, nettement au-dessus des 40 dollars par action proposés.

Chiron a connu de graves problèmes industriels l'an dernier, qui ont fait chuter son cours de Bourse. En octobre, les autorités sanitaires ont découvert un lot de vaccins Fluvirin contre la grippe non conforme à la réglementation dans l'usine britannique de Chiron, à Liverpool. Les ventes vers les Etats-Unis ont immédiatement été suspendues, et Chiron a intégralement raté la saison hivernale américaine. La production devrait pouvoir reprendre pour la grippe de l'hiver prochain. « Novartis pourrait aider à résoudre ces problèmes de fabrication de Fluvirin », estiment les analystes de Merrill Lynch. En s'adossant à un grand groupe, Chiron serait peut-être mieux armé contre ce genre d'aléas. Certains analystes sont sceptiques vis-à-vis de l'opération. Chiron « n'a pas de grand produit leader sur son marché », souligne ainsi l'agence de notation Standard & Poor's.

Le laboratoire suisse poursuit sa stratégie atypique dans le monde des géants de la pharmacie, en diversifiant son portefeuille : génériques, médicaments sans ordonnance, santé animale et maintenant vaccins prennent une place de plus en plus importante dans le chiffre d'affaires. Cette année, la firme suisse a annoncé pour près de 14 milliards de dollars d'acquisitions : 8,4 dans les génériques (l'allemand Hexal et sa filiale américaine Eon Labs), 660 millions dans les médicaments sans ordonnance (ceux de l'américain Bristol-Myers Squibb) et 4,5 pour Chiron. Cette diversification est cependant relative : la firme suisse réalise encore plus de 60 % de son chiffre d'affaires dans les médicaments sous brevet.

Toujours bien noté
La firme bâloise a les moyens de sa stratégie. Même après l'acquisition d'Hexal, Novartis jouit d'une trésorerie nette positive _ elle était de 1,7 milliard de dollars fin juin. Et l'activité de Novartis génère près de 7 milliards de liquidités tous les ans.

Standard & Poor's a d'ailleurs maintenu la note de la société hier, à condition qu'elle ne se lance pas dans d'autres acquisitions payées cash. Pour Fitch, Novartis devrait retrouver une trésorerie nette positive dès la fin de l'année prochaine, s'il réduit ses rachats d'actions.

Novartis est l'une des très rares sociétés au monde à jouir d'une note AAA, la plus élevée possible, aux côtés de ses concurrents Pfizer et Johnson & Johnson.

VINCENT COLLEN
Lire « Crible » page 38. Avec cette OPA, Novartis poursuit sa stratégie, atypique dans le secteur, de diversification. Il mise sur les vaccins en acquérant le californien Chiron, cinquième acteur mondial de cette spécialité.


Grippe Porcine (A) : Le Vaccin Pourrait Etre Plus Dangereux Que La Grippe Elle Même
Dr Russell Blaylock 07/07/09. Copyright www.newsmax.com
http://www.letterfromserendipity.com/BlaylockArticle_IO.pdf traduction française
[...]Novartis, le deuxième concurrent, a également un accord avec l' OMS pour un vaccin contre la pandémie. Novartis semble avoir remporté le contrat, car leur vaccin est bientôt prêt. Ce qui est terrifiant, c'est que ces vaccins contiennent un composant, dénommé adjuvant immunitaire qui est à l'origine de désordres auto immunes dévastateurs, dont l'arthrite rhumatoïde, la sclérose en plaques et le lupus, comme l'ont montré un certain nombre d'études.

Des études basées sur des expérimentations animales utilisant cet adjuvant ont montré qu'il était mortel. Une étude utilisant 14 cochons dinde a trouvé que quand on leur injectait cet adjuvant spécial seul un animal survivait. Une nouvelle étude du même type a abouti au même taux de mortalité.

Alors, quel est ce composant ? Dénommé squalene, c'est un composant huileux. La société Chiron, qui fabrique le vaccin contre l'anthrax mortel, fabrique un adjuvant le MF-59 qui contient deux principaux composants inquiétants - le squalene et le gp120. Un certain nombre d'études ont montré que le squalène peut déclencher, si injecté, toutes les maladies auto immunes citées ci dessus.

Le MF-59 a été utilisé dans plusieurs vaccins.Ces vaccins, dont celui contre le tétanos et la diphtérie, sont les mêmes vaccins fréquemment associés à des réactions négatives.

J'ai passé en revue un certain nombre d'études sur cet adjuvant et j'ai trouvé quelque chose d'intéressant. Plusieurs études réalisées à partir de tests sur des sujets humains ont trouvé que le MF-59 était un adjuvant immunitaire très sur. Mais quand j'ai vérifié pour voir qui avait fait ces études, j'ai trouvé - sans surprise - qu'elles avaient été faites par Novartis Pharmaceutical Cie et Chiron Pharmaceutical Cie, qui ont fusionné.Toutes ont été publiées dans des journaux médicaux "prestigieux". De même, ce qui n'est pas surprenant, un grand nombre d'études faites par des laboratoires indépendants et des instituts de recherche ont tous trouvé un lien entre le MF-59 et des maladies auto immunes.[...]


Novartis Speke ‘flu factory involved in H1N1 production
http://www.liverpoolecho.co.uk/liverpool-news/local-news/2009/07/16/novartis-speke-flu-factory-involved-in-h1n1-production-100252-24168383/
Jul 16 2009 by Neil Hodgson, Liverpool Echo
Add a comment
Recommend

WORK on producing a vaccine for H1N1 swine flu has started at the Novartis factory in Speke.

The Swiss-based drugs giant revealed in its first half results today that all its European sites have started producing a product using traditional egg-based manufacturing, as at Speke, and the faster cell-based product.

First batches have already been produced and clinical trials start this month.

The drugs giant revealed that the US government has already awarded two contracts worth £597m for its H1N1 vaccine and contracts have also been received from other countries.

However, the group revealed that the absence of an anticipated pandemic outbreak of the H5N1 bird flu strain has hit its vaccine sales. Novartis today said that net sales for the first half of 2009 were £12.3bn.

It said currency fluctuations had affected performance levels, but when calculated in local currencies the sales were an eight per cent improvement.

The £2.86bn operating income was 11% up in constant currencies.
A 12% jump in the sales performance of pharmaceuticals helped drive the figures.

And strong momentum in its research and development programme, particularly the anti-cancer therapy Afinitor introduced in the US and awaiting European approval, means the group is confidently predicting record earnings for the full 2009 financial year.

So far second quarter net sales are eight per cent ahead of the previous year at £6.4bn, calculated in local currencies.

Stripping out adverse currency movements the second quarter operating income was 13% ahead at £1.46bn.

Novartis said its performance so far has made it one of the fastest growing pharmaceutical companies in 2009, in terms of local currency net sales.

Its Speke plant, formerly owned by Chiron, employs about 600 staff making conventional ‘flu vaccines for the both the United Kingdom and US markets

1 commentaire:

  1. je suis atteint du syndrome de la guerre du golf après une seule injection de squalene du vaccin PANDEMRIX en2009, http://www.agenceinfolibre.fr/webserie-sur-la-vaccination-3-entretien-avec-yvon-cauchois/

    RépondreSupprimer